Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03058185 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)

Study acronym: OPALE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 28 to 29
    • Collaborators revised (3)
    • Publications: details revised at 2 of 2 entries
    • Eligibility criteria expanded, about 3 words
  2. Minor Study sites revised (28)v13
  3. Minor Study sites: 12 to 28
    • Collaborators expanded, about 20 words
    • Eligibility criteria expanded, about 3 words
    v12
  4. Minor Re-verified, no change to tracked fieldsv11
  5. Notable Primary and study completion dates: Jul 11, 2023 to Jul 11, 2033
    • Site contacts updated at 2 of 12 sites
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor 2 versions Re-verified since Aug 24, 2021, no change to tracked fieldsv8-v9
  2. Minor Study sites: 11 to 12v7
  3. Minor Study sites: 10 to 11
    • Study title revised
    v6
  4. Minor Study sites: 4 to 10v5
  5. Minor Site details revised at 3 of 4 sites
    • Eligibility criteria expanded, about 4 words
    v4
  6. Minor Study sites: 1 to 4v3
  7. Minor Re-verified, no change to tracked fieldsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the description of the clinical and genetic spectrum of these diseases since the 1990's. Until now, precise phenotype/genotype relations remain elusive. As for several other neuromuscular disorders, apart from symptomatic treatments, there is currently no specific treatment to prevent or slow down the progression of the disease. The OPALE registry is a multicentre web-based registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved by ethical and regulatory authorities. Its main inclusion criteria is the presence of a proven pathogenic LMNA and/or EMD gene mutation. The OPALE objectives are to provide a tool allowing detailed capture of patient genetic, neurological, cardiological, endocrinological and respiratory assessments, in order to allow i) precise disease natural history, ii) evaluation of different disease complication frequency and iii) identification of prognosis factors.
Trial Details
NCT Number NCT03058185
Lead Sponsor Pitié-Salpêtrière Hospital
Collaborators: Institut de Myologie, France, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)
Laminopathies, Emerinopathies
Related terms Autosomal Emery-Dreifuss Muscular Dystrophy, Laminopathies, Muscular Dystrophy, Emery-Dreifuss, X-Linked Emery-Dreifuss Muscular Dystrophy
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov